- Home
- TLSI vs BTCS Comparison
TLSI vs BTCS Comparison
Compare TLSI & BTCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- BTCS
- Stock Information
- Founded
- TLSI 2010
- BTCS 2008
- Country
- TLSI United States
- BTCS United States
- Employees
- TLSI N/A
- BTCS N/A
- Industry
- TLSI Medical Specialities
- BTCS Finance: Consumer Services
- Sector
- TLSI Health Care
- BTCS Finance
- Exchange
- TLSI Nasdaq
- BTCS Nasdaq
- Market Cap
- TLSI 244.3M
- BTCS 218.2M
- IPO Year
- TLSI N/A
- BTCS N/A
- Fundamental
- Price
- TLSI $4.55
- BTCS $3.28
- Analyst Decision
- TLSI Strong Buy
- BTCS Strong Buy
- Analyst Count
- TLSI 4
- BTCS 1
- Target Price
- TLSI $11.13
- BTCS $7.00
- AVG Volume (30 Days)
- TLSI 128.4K
- BTCS 2.2M
- Earning Date
- TLSI 11-13-2025
- BTCS 11-11-2025
- Dividend Yield
- TLSI N/A
- BTCS 1.62%
- EPS Growth
- TLSI N/A
- BTCS N/A
- EPS
- TLSI N/A
- BTCS N/A
- Revenue
- TLSI $35,990,000.00
- BTCS $7,522,073.00
- Revenue This Year
- TLSI $56.71
- BTCS $160.41
- Revenue Next Year
- TLSI $52.25
- BTCS $46.15
- P/E Ratio
- TLSI N/A
- BTCS N/A
- Revenue Growth
- TLSI 45.50
- BTCS 354.52
- 52 Week Low
- TLSI $3.42
- BTCS $1.21
- 52 Week High
- TLSI $5.88
- BTCS $8.49
- Technical
- Relative Strength Index (RSI)
- TLSI 37.64
- BTCS 33.47
- Support Level
- TLSI $4.50
- BTCS $3.07
- Resistance Level
- TLSI $4.80
- BTCS $4.30
- Average True Range (ATR)
- TLSI 0.22
- BTCS 0.23
- MACD
- TLSI -0.05
- BTCS -0.11
- Stochastic Oscillator
- TLSI 0.00
- BTCS 14.29
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About BTCS BTCS Inc.
BTCS Inc. ("BTCS" or the "Company"), short for Blockchain Technology Consensus Solutions, is a U.S.-based Ethereum-first blockchain technology company committed to driving scalable revenue and ETH accumulation through its hallmark strategy, the DeFi/TradFi Accretion Flywheel, an integrated approach to capital formation and blockchain infrastructure. By combining decentralized finance ("DeFi") and traditional finance ("TradFi") mechanisms with its blockchain infrastructure operations, comprising NodeOps (staking) and Builder+ (block building), BTCS offers one of the most sophisticated opportunities for leveraged ETH exposure, driven by scalable revenue generation and a yield-focused ETH accumulation strategy. Discover how BTCS offers operational and financial leveraged exposure to Ethereum through the public markets at www.btcs.com.